Vaxcyte, Inc.
PCVX
Rank in Stocks
#2109
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Share Price
$63.40
Last synced: 2026-10-16
Market Cap
$9.72B
Change (1 day)
-2.87%
Change (1 year)
49.56%
Country
US
Trade Vaxcyte, Inc. (PCVX)
Category
Healthcare
Earnings for Vaxcyte, Inc. (PCVX)
Earnings in Jun 2026 TTM: $-1.06B
According to Vaxcyte, Inc. latest financial reports the company's current earnings are $-1.06B. In 2023 the company made an earning of $-402.27M, a decrease compared to its 2022 earnings that were of $-223.49M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Vaxcyte, Inc. from 2017 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-1.06B | 129.40% |
| 2024 | $-463.93M | 15.33% |
| 2023 | $-402.27M | 80.00% |
| 2022 | $-223.49M | 123.31% |
| 2021 | $-100.08M | 12.17% |
| 2020 | $-89.22M | 77.46% |
| 2019 | $-50.27M | 70.51% |
| 2018 | $-29.49M | 71.05% |
| 2017 | $-17.24M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -595.64% |
US
|
|
| $-3.09B | 190.06% |
US
|
|
| $-4.02B | 277.37% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -283.29% |
NL
|
